Welcome to our dedicated page for Firefly Neuroscience news (Ticker: AIFF), a resource for investors and traders seeking the latest updates and insights on Firefly Neuroscience stock.
Firefly Neuroscience, Inc. (NASDAQ: AIFF) is an Artificial Intelligence company in the technology sector that develops EEG- and ERP-based brain analytics platforms for neurological and mental health applications. The Firefly Neuroscience news feed on Stock Titan aggregates company announcements, research updates, financial results, and partnership news that reflect how the business is progressing with commercialization of its FDA-510(k) cleared Brain Network Analytics (BNA™) platform and related technologies.
Investors and followers of AIFF can use this page to review Firefly’s periodic disclosures about revenue trends, EEG/ERP scan volumes, operating expenses, and other financial metrics reported in its earnings releases. Recent news has highlighted revenue growth, reduced operating expenses, and the impact of the company’s acquisition of Evoke Neuroscience, Inc., which expanded Firefly’s EEG/ERP database, patent portfolio, and commercial user base.
Beyond financial reporting, Firefly frequently issues news about scientific and clinical collaborations. Examples include its engagement with the Institute of Human Genetics at Heidelberg University Hospital on EEG biomarker research for 15q13.3 copy number variants, a collaboration with Hemostemix Inc. to use BNA as an exploratory endpoint in a vascular dementia clinical trial, and research demonstrating combined EEG/ERP and volumetric MRI approaches to differentiate stages of cognitive impairment in Alzheimer’s patients.
Company updates also cover technology developments and commercial partnerships, such as the launch of the CLEAR preprocessing platform built on NVIDIA GPU acceleration and a partnership with HealingMaps and Advanced Behavioral Strategies to offer cognitive electrophysiology analytics to a large network of ketamine, psilocybin, and TMS clinics across North America. By monitoring this news page, readers can track how Firefly advances its AI-driven brain analytics, expands its data assets, and pursues its stated goal of building an EEG/ERP-based foundation model of the human brain.
Firefly Neuroscience (NASDAQ: AIFF) has completed its merger with WaveDancer and is now listed on Nasdaq. The company focuses on using AI to improve brain health outcomes through two key strategies:
1. Commercializing FDA-cleared Brain Network Analytics (BNA™) technology for neurologists in the US.
2. Partnering with CNS drug companies to advance new treatments for brain disorders.
BNA™ has shown promising results in patient care, reducing medication changes and improving recovery times. Firefly plans to make BNA™ commercially available to neurologists in 2025. The company has already partnered with Novartis, Takeda, and STALICLA SA, featuring in three publications in 2024. Firefly's proprietary database of over 17,000 patients across 12 disorders gives it a competitive advantage in developing clinical biomarkers.